The study’s strong association between active smoking at proliferative sickle retinopathy (PSR) diagnosis and the condition’s subsequent progression spurred the authors to support smoking cessation and...
July 2026 included several FDA drug and biologic approvals across a range of therapeutic areas. This timeline highlights the key alerts our publication covered throughout the month, giving readers a quick,...
The FDA expanded approval of exagamglogene autotemcel (Casgevy) for patients aged 2 years and older with sickle cell disease and recurrent vaso-occlusive crises or transfusion-dependent β-thalassemia.
...
A new national analysis provides clinicians with evidence on how chronic obstructive pulmonary disease affects post-discharge outcomes in adults with sickle cell disease hospitalized for acute chest...
A new multicenter analysis presented at the 67th American Society of Hematology (ASH) Annual Meeting evaluates how often emergency departments meet national guidelines for timely opioid administration in...
A large contemporary U.S. electronic health record analysis highlights elevated risks of severe maternal morbidity and preterm birth among pregnant individuals with sickle cell disease, offering updated...
A new multicenter UK audit evaluated dapagliflozin use in adults with sickle cell disease–associated chronic kidney disease, offering clinicians early insight into safety, tolerability, and renal effects in...
Explore how value-based care providers can navigate the clinical and financial impact of emerging therapies, biosimilars, and federal drug pricing reforms.
Brain age gap may be a potential biomarker for cognitive impairment, revealing that adults with sickle cell anemia and those from economically deprived backgrounds show signs of premature brain aging linked...
A specialized inpatient sickle cell disease (SCD) consult service led to improved pain management, shorter hospital stays and expanded use of individualized pain plans for patients with SCD.
